A characteristic feature of Parkinson’s disease (PD) is the fact that it is diagnosed only at the late, “clinical” stage due to onset of motor symptoms on the background of almost complete degradation of the dopaminergic nigrostriatal system. This explains the low efficacy of existing replacement therapy (dopamine agonists) and produces the need to develop early (preclinical) diagnosis and use of preventive neuroprotective therapy aimed at slowing neuron death. At the early phase of the preclinical stage of PD, neuroprotective therapy must clearly be provided with cognizance of the level of degradation of the dopaminergic system, and currently this can be achieved only using positron emission tomography, a method which has limited availability. The aim of the present work was therefore to pursue the experimental development of an alternative easily accessible low-invasive approach to assessment of the level of degradation of the dopaminergic system in a model of the preclinical stage of PD. This original approach is based on the search for the minimum dose of α-methyl-p-tyrosine– a reversible dopamine (DA) synthesis inhibitor – which at different phases of the preclinical stage of PD can decrease DA contents to the threshold at which motor function is degraded. Development used an original model of the early and late preclinical stages of PD reproduced in mice with one or two systemic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine – a protoxin which in the body is converted into a substance toxic to dopaminergic neurons. In the former case, the DA level in the striatum decreases to 80%, in the latter to 39% of control/normal, taken as 100%. Studies in these models found the minimum dose of α-methyl-p-tyrosine at which the DA level decreased to the threshold (30%) accompanied by impairment of motor and exploratory activity. The dose in the model of the early preclinical stage was 75 mg/kg, compared with 50 mg/kg for the model of the late preclinical stage. Thus, these studies showed that the extent of degradation of the nigrostriatal dopaminergic system at the preclinical stage of PD can be determined in terms of the minimum dose of the reversible DA synthesis inhibitor at which it elicits a decrease in the DA level in the striatum to the threshold (30%) accompanied by impairment of motor and exploratory activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agid, Y., “Parkinson’s disease: pathophysiology,” Lancet, 337, No. 8753, 1321–1324 (1991).
Albin, R. L., Young, A. B., and Penney, J. B., “The functional anatomy of basal ganglia disorders,” Trends Neurosci., 12, No. 10, 366–375 (1989).
Bailey, K. R. and Crawley, J. N., “Anxiety-related behaviors in mice,” in: Methods of Behavior Analysis in Neuroscience, Chpt. 5 (2009), 2nd ed.
Becker, G., Muller, A., and Braune, S., “Early diagnosis of Parkinson’s disease,” J. Neurol., 249, Supplement, III/40-III/48 (2002).
Bezard, E. and Gross, C. E., “Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach,” Prog. Neurobiol., 55, No. 2, 93–116 (1998).
Bezard, E., Dovero, S., Prunier, C., et al., “Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson’s disease,” J. Neurosci., 21, 6853–6861 (2001).
Bezard, E., Gross, C. E., and Brotchie, J. M., “Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated,” Trends Neurosci., 26, 215–221 (2003).
Bezard, E., Porras, C. G., Blesa, J., and Obeso, J. A., “Compensatory mechanisms in experimental and human parkinsonism: potential for new therapies,” in: Handbook of Basal Ganglia Structure and Function: A Decade of Progress, H. H. Steiner and H. M. Tseng (eds.), Elsevier, San Diego (2010).
Blesa, J., Trigo-Damas, I., Dileone, M., et al., “Compensatory mechanisms in Parkinson’s disease: Circuits adaptations and role in disease modification,” Exp. Neurol., 298, 148–161 (2017).
Bloemen, O. J. N., Brain Markers of Psychosis and Autism: The Brain in Concert: PhD Thesis (2011), pp. 70–89.
Cummings, J. L., Henchcliffe, C., Schaier, S., et al., “The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration,” Brain, 134, No. 11, 3146–3166 (2011).
Directive 2010/63/EU of the European Parliament and of the Council on the Protection of Animals Used for Scientific Purposes, Sept. 22, 2010.
Ehringer, H. and Hornykiewicz, O., “Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system,” Klin. Wochenschr., 4, 1236–1239 (1960).
Engelman, K., Horwitz, D., Jequer, E., and Sjoerdsma, A., “Biochemical and pharmacologic effects of α-methyltyrosine in man,” J. Clin. Invest., 47, No. 1968, 577–594
Gaenslen, A. and Berg, D., “Early diagnosis of Parkinson’s disease,” Int. Rev. Neurobiol., 90, 81–92 (2010).
Gould, T. D., Dao, D. T., and Kovacsics, C. E., “The open field test,” in Mood and Anxiety Related Phenotypes in Mice. Neuromethods, T. Gould (ed.) (2009), p. 42.
Jadvar, H. and Colletti, P. M., “Competitive advantage of PET/MRI,” Eur. J. Radiol., 83, 84–94 (2014).
Kalia, L. V. and Lang, A. E., “Parkinson’s disease,” Lancet, 386, 896–912 (2015).
Khakimova, G. R., Kozina, E. A., Kucheryanu, V. G., and Ugrumov, M. V., “Reversible pharmacological induction of motor symptoms in MPTP-treated mice at the presymptomatic stage of parkinsonism: Potential use for early diagnosis of Parkinson’s disease,” Mol. Neurobiol., 54, No. 5, 3618–3632 (2017).
Kim, A. R. and Ugrumov, M. V., “Changes in blood catecholamine concentrations in experimental models of Parkinson’s disease as a biomarker of the early stage of the disease,” Dokl. Akad. Nauk, 464, No. 4, 494–497 (2015).
Larsson, M., Ohman, R., Wallin, L., et al., “Antipsychotic treatment with alphamethyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools,” J. Neural Transm. (Vienna), 60, 115–132 (1984).
Order of the Russian Federation Ministry of Health of April 1, 2016, No. 199n, On Approval of the Rules for Good Laboratory Practice, registered at the Russian Federation Ministry of Justice, August 15, 2016, Reg. No. 43232.
Paxinos, G. F. and Franklin, K., The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego (2012).
Przedborski, S., Jackson-Lewis, V., Djaldetti, R., et al., “The parkinsonian toxin MPTP: action and mechanism,” Restor. Neurol. Neuroscientist, 16, No. 2, 135–142 (2000).
Rehman, M. U., Wali, A. F., Ahmad, A., et al., “Neuroprotective strategies for neurological disorders by natural products: An update,” Curr. Neuropharmacol. (2018), Epub ahead of print.
Safandeev, V. V., Kolacheva, A. A., Ivanov, D. E., and Ugrumov, M. V., “Detection of the latent functional inadequacy of dopaminergic neurons of the nigrostriatal system in a chronic model of Parkinson’s disease,” Neirokhimiya, 34, No. 4, 290–295 (2017).
Sjoerdsma, A., Engelman, K., Spector, S., and Udenfriend, S., “Inhibition of catecholamine synthesis in man with alpha methyl-tyrosine, an inhibitor of tyrosine hydroxylase,” Lancet, 2, 1092 (1965).
Spector, S., Sjoerdsma, A., and Udenfriend, S., “Blockade of endogenous norepinephrine synthesis by α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase,” J. Pharmacol. Exp. Ther., 147, 86–95 (1965).
Tripathi, M., Kumar, A., and Bal, C., “Neuroimaging in Parkinsonian Disorders,” Neurol. India, 66, No. 7, 68–78 (2018).
Ugrumov, M. V., Khaindrava, V. G., Kozina, et al., “Modeling of presymptomatic and symptomatic stages of parkinsonism in mice,” Neuroscience,181, 175–188 (2011).
Verger, A., Klesse, E., Chawki, M. B., et al., “Brain PET substrate of impulse control disorders in Parkinson’s disease: A metabolic connectivity study,” Hum. Brain Mapp. (2018), Epub ahead of print.
Werner, P., Barthel, H., Drezezga, A., and Sabri, O., “Current status and future role of brain PET/MRI in clinical and research settings,” Eur. J. Nucl. Med. Mol. Imaging, 42, 512–516 (2015).
Zigmond, M. J., “Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism,” Neurobiol. Dis., 4, 247–253 (1997).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Vysshei Nervnoi Deyatel’nosti imeni I. P. Pavlova, Vol. 69, No. 3, pp. 382–392, May–June, 2019.
Rights and permissions
About this article
Cite this article
Safandeev, V.V., Ugrumov, M.V. A New Approach to Assessing the Extent of Degradation of the Nigrostriatal Dopaminergic System in an Experimental Model of Parkinson’s Disease. Neurosci Behav Physi 50, 451–458 (2020). https://doi.org/10.1007/s11055-020-00920-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-020-00920-3